Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis

Amit Badiye, Gabriel A. Hernandez, Sandra Chaparro

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The growing use of left ventricular assist devices as a bridge to transplant and their increased duration as destination therapy in patients successfully treated for advance heart failure unwrap a new spectrum of complications seen in long-term use of the devices. Device thrombosis remains a therapeutic dilemma, and limited data are available for the use of direct thrombin inhibitors as a treatment option. We performed a review of literature and present a series of four patients with suspected left ventricular assist device-associated thrombosis, manifesting as hemolysis, who were treated empirically with argotraban, a direct thrombin inhibitor with the ability to interact with both free and clot-bound thrombin. In this case series, we treated four patients with argatroban for suspected device thrombosis. All showed significant improvement of hemolysis according to lactate dehydrogenase measurements, and device removal was prevented in three. Bleeding complications occurred when therapy was used closer to the operative period. Argatroban can be a viable option to treat patients with hemolysis from suspected device thrombosis in patients with HeartMate II continuous-flow left ventricular assist device. Prompt attention is needed to monitor any bleeding complications.

Original languageEnglish
Pages (from-to)361-365
Number of pages5
JournalASAIO Journal
Volume60
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Left ventricular assist devices
Heart-Assist Devices
Hemolysis
Heart Ventricles
Thrombosis
Antithrombins
Equipment and Supplies
Transplants
L-Lactate Dehydrogenase
Thrombin
Device Removal
Hemorrhage
Therapeutics
Heart Failure
argatroban

Keywords

  • Anticoagulation
  • heart
  • heart failure
  • thrombosis
  • ventricle assist device

ASJC Scopus subject areas

  • Biophysics
  • Biomaterials
  • Bioengineering
  • Biomedical Engineering
  • Medicine(all)

Cite this

Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. / Badiye, Amit; Hernandez, Gabriel A.; Chaparro, Sandra.

In: ASAIO Journal, Vol. 60, No. 3, 01.01.2014, p. 361-365.

Research output: Contribution to journalArticle

@article{9c43d04ed9af4c0696fe17c12c582f0e,
title = "Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis",
abstract = "The growing use of left ventricular assist devices as a bridge to transplant and their increased duration as destination therapy in patients successfully treated for advance heart failure unwrap a new spectrum of complications seen in long-term use of the devices. Device thrombosis remains a therapeutic dilemma, and limited data are available for the use of direct thrombin inhibitors as a treatment option. We performed a review of literature and present a series of four patients with suspected left ventricular assist device-associated thrombosis, manifesting as hemolysis, who were treated empirically with argotraban, a direct thrombin inhibitor with the ability to interact with both free and clot-bound thrombin. In this case series, we treated four patients with argatroban for suspected device thrombosis. All showed significant improvement of hemolysis according to lactate dehydrogenase measurements, and device removal was prevented in three. Bleeding complications occurred when therapy was used closer to the operative period. Argatroban can be a viable option to treat patients with hemolysis from suspected device thrombosis in patients with HeartMate II continuous-flow left ventricular assist device. Prompt attention is needed to monitor any bleeding complications.",
keywords = "Anticoagulation, heart, heart failure, thrombosis, ventricle assist device",
author = "Amit Badiye and Hernandez, {Gabriel A.} and Sandra Chaparro",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/MAT.0000000000000067",
language = "English",
volume = "60",
pages = "361--365",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis

AU - Badiye, Amit

AU - Hernandez, Gabriel A.

AU - Chaparro, Sandra

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The growing use of left ventricular assist devices as a bridge to transplant and their increased duration as destination therapy in patients successfully treated for advance heart failure unwrap a new spectrum of complications seen in long-term use of the devices. Device thrombosis remains a therapeutic dilemma, and limited data are available for the use of direct thrombin inhibitors as a treatment option. We performed a review of literature and present a series of four patients with suspected left ventricular assist device-associated thrombosis, manifesting as hemolysis, who were treated empirically with argotraban, a direct thrombin inhibitor with the ability to interact with both free and clot-bound thrombin. In this case series, we treated four patients with argatroban for suspected device thrombosis. All showed significant improvement of hemolysis according to lactate dehydrogenase measurements, and device removal was prevented in three. Bleeding complications occurred when therapy was used closer to the operative period. Argatroban can be a viable option to treat patients with hemolysis from suspected device thrombosis in patients with HeartMate II continuous-flow left ventricular assist device. Prompt attention is needed to monitor any bleeding complications.

AB - The growing use of left ventricular assist devices as a bridge to transplant and their increased duration as destination therapy in patients successfully treated for advance heart failure unwrap a new spectrum of complications seen in long-term use of the devices. Device thrombosis remains a therapeutic dilemma, and limited data are available for the use of direct thrombin inhibitors as a treatment option. We performed a review of literature and present a series of four patients with suspected left ventricular assist device-associated thrombosis, manifesting as hemolysis, who were treated empirically with argotraban, a direct thrombin inhibitor with the ability to interact with both free and clot-bound thrombin. In this case series, we treated four patients with argatroban for suspected device thrombosis. All showed significant improvement of hemolysis according to lactate dehydrogenase measurements, and device removal was prevented in three. Bleeding complications occurred when therapy was used closer to the operative period. Argatroban can be a viable option to treat patients with hemolysis from suspected device thrombosis in patients with HeartMate II continuous-flow left ventricular assist device. Prompt attention is needed to monitor any bleeding complications.

KW - Anticoagulation

KW - heart

KW - heart failure

KW - thrombosis

KW - ventricle assist device

UR - http://www.scopus.com/inward/record.url?scp=84900465401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900465401&partnerID=8YFLogxK

U2 - 10.1097/MAT.0000000000000067

DO - 10.1097/MAT.0000000000000067

M3 - Article

VL - 60

SP - 361

EP - 365

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -